BioXcel Therapeutics Inc BTAI:NASDAQ

Earnings Announcement Next Earnings date is expected on 08/09/2022
Last Price$15.94Cboe Real-Time Last Sale as of 1:20PM ET 8/08/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.47(2.86%)
Bid (Size)$15.93 (32)
Ask (Size)$16.03 (102)
Day Low / High$15.75 - 16.81
Volume230.0 K
 

View Biotechnology IndustryPeer Comparison as of 08/08/2022

 

BioXcel Therapeutics Inc ( NASDAQ )

Price: $15.94
Change: -0.47 (2.86%)
Volume: 230.0 K
1:20PM ET 8/08/2022
 
 

MeiraGTx Holdings PLC ( NASDAQ )

Price: $9.73
Change: -0.62 (5.99%)
Volume: 52.2 K
1:06PM ET 8/08/2022
 
 

MiMedx Group Inc ( NASDAQ )

Price: $4.10
Change: +0.16 (4.06%)
Volume: 381.3 K
1:20PM ET 8/08/2022
 
 

Scholar Rock Holding Corp ( NASDAQ )

Price: $8.31
Change: -0.19 (2.24%)
Volume: 143.6 K
1:19PM ET 8/08/2022
 
 

Radius Health Inc ( NASDAQ )

Price: $10.14
Change: -0.05 (0.54%)
Volume: 315.7 K
1:10PM ET 8/08/2022
 

Read more news Recent News

BioXcel Therapeutics Says Columbia University Gets NIH Grant to Test BXCL501 to Treat Opioid Withdrawal
10:10AM ET 8/01/2022 MT Newswires

BioXcel Therapeutics (BTAI) said Monday the National Institute on Drug Abuse, which is part of the National Institutes of Health, has awarded Columbia...

--Mizuho Securities Initiates BioXcel Therapeutics at Buy with $19 Price Target
10:27AM ET 7/07/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Mizuho Initiates BioXcel Therapeutics With Buy Rating, $19 Price Target, Transitioning To 'Revenue-Generating' Story
4:10PM ET 7/06/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Berenberg Bank Terminates Coverage of 85 Companies in Consumer Discretionary, Healthcare, Industrial Tech, REIT, Software and IT Services Sectors
8:41AM ET 7/01/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionBioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology. The firm offers IGALMI, a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults. It also develops BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of prostate cancer and solid tumors that are refractory to checkpoint inhibitors. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT. View company web site for more details
Address555 Long Wharf Drive
New Haven, Connecticut 06511
Phone+1.475.238.6837
Number of Employees18
Recent SEC Filing07/21/20228-K
President, Chief Executive Officer & DirectorVimal D. Mehta
Chief Financial Officer & Vice PresidentRichard I. Steinhart
Chief Scientific Officer & Senior Vice PresidentFrank D. Yocca
Chief Medical Officer & Senior Vice PresidentVincent J. O'Neill

Company Highlights

Price Open$16.60
Previous Close$16.41
52 Week Range$8.80 - 36.49
Market Capitalization$446.1 M
Shares Outstanding28.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/09/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.10
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-48.25%

Analyst Ratings as of 07/05/2022

Buy
8
Overweight
0
Hold
0
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset